

UNITED STATE DEPARTMENT OF COMMERCE United States Pat int and Trad mark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231

						<u> يمو</u>
1	APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR		ATTORNEY DOCKET NO).
•	087815 773	03/12/91	7 BAUMGARTNER	.J	95-33	

HM22/0507

GARY E PARKER ZYMOGENETICS INC 1201 EASTLAKE AVENUE EAST SEATTLE WA 98102

· EXAMINEN						
LAZAR WESLEY,E						
ART UNIT	PAPER NUMBER					
1646	16.					

DATE MAILED:

05/07/01

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks

Office Action Summary

Application No. 08/815,773

Eliane Lazar-Wesley

Examiner

Applica...(s)

Art Unit 1646

Baumgartner



The MAILING DATE of this communication appe	ears on the cover sheet with the correspondence address
 after SIX (6) MONTHS from the mailing date of this comm If the period for reply specified above is less than thirty (30) of be considered timely. If NO period for reply is specified above, the maximum statutic communication. Failure to reply within the set or extended period for reply will 	7 CFR 1.136 (a). In no event, however, may a reply be timely filed
Status 1) Responsive to communication(s) filed on	·
	action is non-final.
3) Since this application is in condition for allowand closed in accordance with the practice under Ex	ce except for formal matters, prosecution as to the merits is parte Quayle, 1935 C.D. 11; 453 O.G. 213.
Disposition of Claims	
4) 💢 Claim(s) 33-38	is/are pending in the application.
4a) Of the above, claim(s)	is/are withdrawn from consideration.
5) Claim(s)	
	is/are rejected.
	is/are objected to.
	are subject to restriction and/or election requirement.
Application Papers 9) The specification is objected to by the Examiner 10) The drawing(s) filed on is/ 11) The proposed drawing correction filed on 12) The oath or declaration is objected to by the Examiner	are objected to by the Examiner. is: a)□ approved b)□ disapproved.
_	have been received. have been received in Application No y documents have been received in this National Stage ureau (PCT Rule 17.2(a)).
14) Acknowledgement is made of a claim for domes	
Attachment(s)	
15) X Notice of References Cited (PTO-892)	18) Interview Summary (PTO-413) Paper No(s).
16 Notice of Draftsperson's Patent Drawing Review (PTO-948) 17 Information Disclosure Statement(s) (PTO-1449) Paper No(s).	19) Notice of Informal Patent Application (PTO-152) 20) Other:

Art Unit: 1646

DETAILED ACTION

1. Prosecution is reopened.

Claims 33-38 are pending.

Claim Rejections - 35 USC § 102

2. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless --

(e) the invention was described in a patent granted on an application for patent by another filed in the United States before the invention thereof by the applicant for patent, or on an international application by another who has fulfilled the requirements of paragraphs (1), (2), and (4) of section 371(c) of this title before the invention thereof by the applicant for patent.

3. Claims 33-38 are rejected under 35 U.S.C. 102(e) as being anticipated by Collins et al., US Patent 5,710,023, January 20, 1998 or Collins et al., US Patent 6,214,559 B1, April 10, 2001, claiming priority to March 01, 1996.

Claims 33-38 are to a method of detecting a ligand, wherein the ligand binds to a polypeptide having amino acid residues 141-337 of SEQ ID No:2, or amino acids 25-337 of SEQ ID No:2. The amino acid sequence of the instant SEQ ID No:2 is 100% identical over its entire length to SEQ ID No:4 of the Collins patents (see sequence comparison, attached).

Collins teaches an IL13-bc protein of SEQ ID No:4, which is a receptor that binds the ligand IL13 (col.4, lines 53-63). The IL13-bc protein of SEQ ID No:4 comprises a putative signal sequence, an extracellular domain, a transmembrane domain, and an intracellular domain (col.4, lines 12-22).

Application/Control Number: 08/815,773 Page 3

Art Unit: 1646

He teaches that a number of types of cells act a suitable host cells for expression of the IL13-bc protein (col.5, lines 47-57), and that the polypeptide can be immobilized on solid support (col.6, lines 47+). The limitations of the claims are met.

4. No claim is allowed.

5. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Eliane Lazar-Wesley, PhD, whose telephone number is (703) 305 4059. The examiner can normally be reached on Monday-Friday from 9:30am to 5pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Yvonne Eyler, can be reached on (703) 308-6564.

Official papers filed by fax should be directed to (703) 308 4242. Faxed draft or informal communications with the examiner should be directed to (703) 308-0294.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Group receptionist whose telephone number is (703) 308-0196.

ELW

April 30, 2001

EW

YVONNE EYLER, PH.D SUPERVISORY PATENT EXAMINER TECHNOLOGY CENTER 1600